Patient characteristics
| ≤10 cabazitaxel cycles n=25 | >10 cabazitaxel cycles n=20 | Overall N=45 | |
| Age, years, median (range) | 72 (41–86) | 70 (57–85) | 71 (41–86) |
| Age group, years, n (%) | |||
| <65 | 3 (12) | 5 (25) | 8 (11) |
| 65–74 | 11 (44) | 11 (55) | 22 (49) |
| ≥75 | 11 (44) | 4 (20) | 15 (33) |
| ECOG performance status, n (%) | |||
| 0 or 1 | 11 (44) | 13 (65) | 23 (51) |
| 2 | 14 (56) | 7 (35) | 22 (49) |
| Gleason score, n (%)/42* | |||
| ≤6 | 1 (4) | 1 (5) | 2 (5) |
| ≥7 | 22 (88) | 18 (90) | 40 (95) |
| PSA, ng/mL/44*, median (range) | 130 (0.07–1220) | 33 (2.1–1240) | 85.50 (0.07–1240) |
| LDH levels, n (%)/43* | |||
| Normal | 12 (50) | 14 (74) | 26 (58) |
| >ULN | 12 (50) | 5 (26) | 17 (43) |
| Elevated ALP, n (%)/42* | 14 (56) | 10 (50) | 24 (56) |
| Haemoglobin, <LLN, n (%) | 20 (80) | 18 (90) | 38 (84) |
| Metastases, n (%) | |||
| Bone | 24 (96) | 20 (100) | 44 (98) |
| Lymph nodes | 4 (16) | 8 (40) | 12 (27) |
| Lungs | 1 (4) | 1 (5) | 2 (4) |
| Liver | 3 (12) | 2 (10) | 5 (11) |
| Prior hormonal therapy, n (%)/43* | |||
| 1 regimen | 15 (65) | 12 (60) | 27 (64) |
| 2 regimens | 7 (30) | 7 (35) | 14 (33) |
| ≥3 regimens | 1 (4) | 1 (5) | 2 (5) |
| Prior radiation, n (%)/35* | |||
| Curative | 6 (24) | 3 (15) | 9 (26) |
| Palliative | 15 (60) | 6 (30) | 21 (60) |
| Both | 4 (16) | 1 (5) | 5 (14) |
| Prior chemotherapy, n (%) | |||
| Docetaxel | 25 (100) | 20 (100) | 45 (100) |
| Mitoxantrone | 1 (4) | 0 | 1 (2) |
| Prior AAI, n (%) | |||
| Enzalutamiden | 2 (8) | 6 (30) | 8 (18) |
| Abiraterone | 7 (28) | 2 (10) | 9 (20) |
| Enzalutamide and abiraterone | 3 (7) | 1 (5) | 4 (9) |
| Number of docetaxel treatment, median (range) | 10 (5–20) | 7 (2–10) | 9 (2–20) |
| Time from last docetaxel to the start of cabazitaxel, months, median (range) | 9 (0.75–39) | 6 (0.75–120) | 7 (0.75–120) |
| Metastatic prognostic index, n (%)/441 | |||
| Low | 1 (4) | 1 (5) | 2 (5) |
| Intermediate | 3 (13) | 6 (30) | 9 (21) |
| High | 20 (83) | 13 (65) | 33 (75) |
| Subsequent life-prolonging drugs, n (%) | |||
| Abiraterone | 4 (16) | 8 (40) | 12 (27) |
| Enzalutamide | 4 (16) | 2 (10) | 6 (13) |
*Actual number of patients evaluated.
AAI, androgen axis inhibitors; ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; LLN, lower limit of normal; PSA, prostate-specific antigen; ULN, upper limit of normal.